A Break-Even Year For US FDA Advisory Committees?
Executive Summary
Meetings have continued to be sparse through 2021, but there will end up being nearly as many panels on withdrawing approved uses as on approving new ones.
You may also be interested in...
Makena Follows Avastin’s Path With US FDA Hearing On Accelerated Approval Withdrawal
Chief scientist Denise Hinton will decide the fate of Covis’ preterm birth prevention drug because acting commissioner Janet Woodcock has recused herself; CBER deputy director Celia Witten is tapped to serve as presiding officer at the hearing, which will be only the second of its kind under accelerated approval regulations.
The US FDA’s Advisory Committee Drought
FDA’s external advisory committee process is under increasing scrutiny within the agency and by the public – and the agency is continuing to be very sparing in convening actual reviews.
Rx Import Legislation: One Step Forward, Two Steps Back – And Odd Dance Partners
The strange politics of prescription drug importation legislation in the US are on display again, this time in the context of the FDA user fee reauthorization bill. Including the topic in the bill is a ‘big deal’ – but probably makes imports less likely.